Our Research

November 30, 2009

Hybrid BioSystems implements new iLabber electronic lab book system, for maximum IP protection and secure data storage

October 5, 2009

Hybrid BioSystems presents at World Vaccine Congress in Lyon, 5th October 2009. Click here to download the presentation.

November 24, 2009

Hybrid BioSystems Scientific co-founder, Dr Kerry Fisher is awarded Young Investigator Award, European Society of Gene and Cell Therapy November 2009.
http://www.esgct.eu/awards/2009-winners/

November 25, 2009

Hybrid BioSystems renamed and organisation changes announced. Click here to download the official announcement.

March 12, 2009

Hybrid BioSystems offers bespoke virology services, click here for the latest flyer or go to the virology services webpage.

Testimonials

"I have been very impressed with the work you've done for us and if I need any more viruses bulking up in future I will definitely be in contact."
- Custom Adenovirus production for a UK Government Agency

"We just had some adenovirus vectors made at Hybrid Systems and were happy to find they delivered on time"
- Custom Adenovirus production for a large Pharma company

"Many thanks for the virus again, we are very pleased with your viruses as they have always worked well and we haven't had any problems unlike the previous company we used"
- Custom Adenovirus production for a London University group

"We were delighted to receive our virus today, on time and all nicely packaged"
- Custom Adenovirus production for a Birmingham University group

Welcome to the Hybrid BioSystems website

Hybrid is an Oxford Biotechnology Company focused on revolutionising viral vaccines with our patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxfordshire, which houses both our corporate research facility and contract research services.

Using a mixed product and platform business model we are developing our in-house lead products towards phase I/II proof of concept clinical trials as well as furthering our partnerships with leading pharmaceutical and biotechnology companies. Hybrid’s experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding.

With our unparalleled expertise in the field of viral stealthing technologies, we are also able to offer general and bespoke virology services, including high-quality adenovirus production and purification.

Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage.

Latest

February 22, 2010

Hybrid BioSystems launches HBS Services, a dedicated website for the expanding services offered by Hybrid. Click here to find out more.

November 25, 2009

Hybrid BioSystems renamed and organisation changes announced. Click here for the announcement letter.

November 24, 2009

Hybrid BioSystems Scientific co-founder, Dr Kerry Fisher is awarded young Investigator Award, European Society of Gene and Cell Therapy Nov 2009

http://www.esgct.eu/awards/2009-winners/

October 5, 2009

Hybrid Biosystems presents at the World Vaccine Congress in Lyon, October 5th. Click here to download the presentation (3Mb pptx).